Table 2. Pretreatment HRCT findings, by study group. Belém, Brazil, 2015.a .
| Variable | Group | p* | |
|---|---|---|---|
| MABSC (n = 17) | NTM (n = 26) | ||
| Pulmonary involvement | |||
| Absent | 1 (5.9) | 0 (0.0) | |
| Unilateral | 4 (23.5) | 7 (26.9) | 0.4772 |
| Bilateral | 12 (70.6) | 19 (73.1) | |
| Cavitation | |||
| Absent | 8 (47.1) | 11 (42.3) | 0.7369 |
| Single | 4 (23.5) | 9 (34.6) | |
| Multiple | 5 (29.4) | 6 (23.1) | |
| Distribution of cavitation | |||
| Unilobar | 7 (77.8) | 10 (66.7) | 0.2555 |
| Bilobar | 0 (0.0) | 3 (20.0) | |
| Multilobar | 2 (22.2) | 2 (13.3) | |
| Bronchiectasis | |||
| Absent | 1 (5.9) | 4 (15.4) | 0.3376 |
| Present | 11 (64.7) | 11 (42.3) | |
| Present (subsequent NTM infection) | 5 (29.4) | 11 (42.3) | |
| Radiological presentation | |||
| Fibrocavitary | 7 (41.2) | 14 (53.8) | 0.6163 |
| Nodular bronchiectasis | 10 (58.8) | 12 (46.2) | |
MABSC: Mycobacterium abscessus complex; and NTM: mycobacteria other than M. tuberculosis and MABSC. aValues expressed as n (%). *Chi-square test or G-test, as appropriate.